In conclusion, we have developed p54 (viral antigen) and CpG (a TLR-9 agonist) co-loaded PLGA NVs coated with CpG and mannose co-modified RBC membrane, which could be served as an effective and safe manner to boost protective immunity against virus infection. Here, TLR9 is linked to viral infectious disease.